177Lu-DOTATATE治疗神经内分泌瘤患者对环境辐射安全的研究进展

doi:10.7538/tws.2021.youxian.047

同位素 ›› 2022, Vol. 35 ›› Issue (2): 128-134.DOI: 10.7538/tws.2021.youxian.047

¹⁷⁷Lu-DOTATATE治疗神经内分泌瘤患者对环境辐射安全的研究进展

麻广宇;巴建涛;彭程;陈英茂

解放军总医院第一医学中心，北京100853；中国医学科学院协和医院，北京100005；首都医科大学宣武医院，北京100053

出版日期:2022-04-20 发布日期:2022-04-20

Research Progress of ¹⁷⁷Lu-DOTATATE in the Treatment of Neuroendocrine Tumor Patients with Environmental Radiation Safety

MA Guangyu;BA Jiantao;PENG Cheng;CHEN Yingmao

First Medical Center of Chinese PLA General Hospital, Beijing 100853, China;Union Hospital of Chinese Academy of Medical Sciences, Beijing 100005, China;Xuanwu Hospital of Capital Medical University, Beijing 100053, China

Online:2022-04-20 Published:2022-04-20

摘要/Abstract

摘要： 神经内分泌肿瘤是一种起源于分布全身的神经内分泌细胞的肿瘤。¹⁷⁷Lu-DOTATATE已被证明可以显著延长患者无进展生存期，在国外得到了广泛的应用。国外对¹⁷⁷Lu-DOTATATE治疗的辐射安全方面已有较多的研究。国内暂无同类产品上市，且无辐射安全方面的研究，缺少相关的国家标准。本文对近年来国外¹⁷⁷Lu-DOTATATE治疗中与辐射安全相关的研究、法规及管理要求等方面资料进行分析和综述，以期为我国¹⁷⁷Lu-DOTATATE治疗的辐射安全管理规范和标准的制定提供参考。

关键词: ¹⁷⁷Lu-DOTATATE, 神经内分泌瘤, 辐射安全

Abstract: Neuroendocrine tumors (NENs) are rare tumors arising from neuroendocrine cells distributed throughout the body. ¹⁷⁷Lu-DOTATATE has been shown to significantly prolong the progression-free survival of patients, and has been widely used abroad. There are many studies on the radiation safety of ¹⁷⁷Lu-DOTATATE treatment abroad. There are no similar products on the market in China, and there is no research on radiation safety, and there is a lack of relevant national standards. This paper analyzes and summarizes the research, regulations and management requirements related to radiation safety in ¹⁷⁷Lu-DOTATATE treatment abroad in recent years, so as to provide reference for the formulation of radiation safety management norms and standards for¹⁷⁷Lu-DOTATATE treatment in China.

Key words: ¹⁷⁷Lu-DOTATATE, neuroendocrine tumor, radiation safety

麻广宇, 巴建涛, 彭程, 陈英茂. ¹⁷⁷Lu-DOTATATE治疗神经内分泌瘤患者对环境辐射安全的研究进展[J]. 同位素, 2022, 35(2): 128-134.

MA Guangyu, BA Jiantao, PENG Cheng, CHEN Yingmao. Research Progress of ¹⁷⁷Lu-DOTATATE in the Treatment of Neuroendocrine Tumor Patients with Environmental Radiation Safety[J]. Journal of Isotopes, 2022, 35(2): 128-134.

参考文献

［1］Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States［J］. JAMA Oncol, 2017, 3(10): 1335-1342.
［2］Reubi J C, Schonbrunn A. Illuminating somatostatin analog action at neuroendocrine tumor receptors［J］. Trends Pharmacol Sci, 2013, 34(12): 676-688.
［3］Pavel M, Berg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up［J］. Ann Oncol, 2020, 31(7): 844-860.
［4］Hope T A, Abbott A, Colucci K, et al. NANETS/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with 177Lu-dotatate［J］. J Nucl Med, 2019, 60(7): 937-943.
［5］Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of ¹⁷⁷Lu-dotatate for midgut neuroendocrine tumors［J］. New England Journal of Medicine, 2017, 376(2): 125-135.
［6］Kendi A T, Halfdanarson T R, Packard A, et al. Therapy with¹⁷⁷Lu-dotatate: dlinical implementation and impact on care of patients with neuroendocrine tumors［J］. AJR Am J Roentgenol, 2019, 213(2): 309-317.
［7］Levart D, Kalogianni E, Corcoran B, et al. Radiation precautions for inpatient and outpatient¹⁷⁷Lu-Dotatate peptide receptor radionuclide therapy of neuroendocrine tumours［J］. EJNMMI Physics, 2019, 6:7.
［8］Barrington S F, Kettle A G, O’Doherty M J, et al. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid［J］. Eur J Nucl Med, 1996,23:123-130.
［9］International Atomic Energy Agency. Practical guidance on peptide receptor radionuclide therapy (PRRNT) for neuroendocrine tumours［M］. Vienna: International Atomic Energy Agency, 2013: 97-123.
［10］Bodei L, Mueller-Brand J, Baum R P, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours［J］. Eur J Nucl Med Mol Imaging, 2013, 40(5): 800-816.
［11］Calais P J, Turner J H. Radiation safety of outpatient ¹⁷⁷Lu-octreotate radiopeptide therapy of neuroendocrine tumors［J］. Ann Nucl Med, 2014, 28: 531-539.
［12］Olmstead C, Cruz K, Stodilka R, et al. Quantifying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol［J］. Nucl Med Commun, 2015, 36: 129-134.
［13］Basu S, Chakraborty S, Parghane R V, et al. One decade of ‘Bench-to-Bedside’ peptide receptor radionuclide therapy with indigenous ［(177)Lu］ Lu-Dotatate obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting［J］. Am J Nucl Med Mol Imaging, 2020, 10(4): 178-211.
［14］Ludwig-Maximilians-Universitt München. Therapy of neuroendocrine tumors (NET) ［EB/OL］. ［2021-01-17］. http:∥www.klinikum.uni-muenchen. de/Klinik-und-Poliklinik-fuer-Nuklearmedizin/en/Nuclear-Medicine-Therapy/therapy-of-neuroen-docrine-tumors/index.html
［15］Lawal I, Louw L, Warwick J, et al. The College of nuclear physicians of south africa practice guidelines on peptide receptor radionuclide therapy in neuroendocrine tumours［J］. S Afr J Surg, 2018, 56(3): 55-64.
［16］易艳玲,石洪成,陈波,等. 分化型甲状腺癌患者的¹³¹I有效半衰期［J］. 原子能科学技术,2010,44(增刊):612-615.
Yi Yanling, Shi Hongcheng, Chen Bo, et al. Effective half-life of ¹³¹I in patients with differentiated thyroid cancer［J］. Atomic Energy Science and Technology, 2010, 44(Sup): 612-615(in Chinese).
［17］Lim L E, Chan D L, Thomas D, et al. Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours［J］. Oncotarget, 2020, 11(27): 2636-2646.
［18］Hosono M, Ikebuchi H, Nakamura Y, et al. Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)［J］. Ann Nucl Med, 2018, 32(3): 217-235.
［19］International Atomic Energy Agency. Release of patients after radionuclide therapy［M］. Vienna: International Atomic Energy Agency, 2009: 5-24.
［20］International Atomic Energy Agency. Radiation protection and safety of radiation sources: international basic safety standards［M］. Vienna: International Atomic Energy Agency, 2014: 18-30.
［21］Ec Kerman K, Harrison J, Menzel H G, et al. ICRP Publication 119: Compendium of dose coefficients based on ICRP publication 60［J］. Ann: ICRP, 2012, 41(Sup): 1-130.

¹⁷⁷Lu-DOTATATE治疗神经内分泌瘤患者对环境辐射安全的研究进展

Research Progress of ¹⁷⁷Lu-DOTATATE in the Treatment of Neuroendocrine Tumor Patients with Environmental Radiation Safety

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics